DECLARE-TIMI 58 Sub-analyses: Expanding Evidence of Cardiovascular Protection across Broad Spectrum of Patients

Earlier Treatment Intervention in Heart Failure Patients Results in Improved Outcomes

Large PIONEER-HF Trial Validates Safety and Benefits of In-Hospital Initiation of Therapeutic Treatment

DECLARE-TIMI 58: Latest SGLT2 Cardiovascular Trial Supports Benefits beyond Glucose Control

Latebreaker Trial Shows Heart Failure Recovery Is Remission and Not a Cure

Once Stable, Many Decompensated Heart Failure Patients Can Be Initiated on Life-Saving Medication

Ensuring that All Heart Failure Patients Receive Optimal Treatment

CCS Guidelines for the Management of Heart Failure: 2017 Comprehensive Update

Progress in Isolating the Mechanisms of New Standards in Heart Failure Therapy

CANTOS Trial Advances Inflammatory Hypothesis of Coronary Artery Disease

PCSK9 Inhibitors Outcomes Data: Definitive CV Protection

Reduced All-Cause Death Suggests SGLT-2 Inhibitors May Be Part of New Anti-Diabetes Standard